161 related articles for article (PubMed ID: 20158477)
61. Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer.
Tzou YM; Bailey SK; Yuan K; Shin R; Zhang W; Chen Y; Singh RK; Shevde LA; Krishna NR
Bioorg Med Chem Lett; 2016 Feb; 26(4):1237-44. PubMed ID: 26803204
[TBL] [Abstract][Full Text] [Related]
62. Complexes of gamma-tubulin with nonreceptor protein tyrosine kinases Src and Fyn in differentiating P19 embryonal carcinoma cells.
Kukharskyy V; Sulimenko V; Macůrek L; Sulimenko T; Dráberová E; Dráber P
Exp Cell Res; 2004 Aug; 298(1):218-28. PubMed ID: 15242776
[TBL] [Abstract][Full Text] [Related]
63. Clinical relevance of targeted interference with Src-mediated signal transduction events.
Ly QP; Yeatman TJ
Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
[No Abstract] [Full Text] [Related]
64. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.
Hill ZB; Perera BG; Maly DJ
Mol Biosyst; 2011 Feb; 7(2):447-56. PubMed ID: 21060940
[TBL] [Abstract][Full Text] [Related]
65. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture.
Fang L; Vilas-Boas J; Chakraborty S; Potter ZE; Register AC; Seeliger MA; Maly DJ
ACS Chem Biol; 2020 Jul; 15(7):2005-2016. PubMed ID: 32479050
[TBL] [Abstract][Full Text] [Related]
66. Src-family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases.
Zhai Y; Yang J; Zhang J; Yang J; Li Q; Zheng T
Int J Med Sci; 2021; 18(5):1216-1224. PubMed ID: 33526983
[TBL] [Abstract][Full Text] [Related]
67. Acquisition of a "Group A"-selective Src kinase inhibitor via a global targeting strategy.
Hah JM; Sharma V; Li H; Lawrence DS
J Am Chem Soc; 2006 May; 128(18):5996-7. PubMed ID: 16669643
[TBL] [Abstract][Full Text] [Related]
68. Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors.
Leonard SE; Register AC; Krishnamurty R; Brighty GJ; Maly DJ
ACS Chem Biol; 2014 Aug; 9(8):1894-905. PubMed ID: 24946274
[TBL] [Abstract][Full Text] [Related]
69. Src family kinases and pulmonary fibrosis: A review.
Li H; Zhao C; Tian Y; Lu J; Zhang G; Liang S; Chen D; Liu X; Kuang W; Zhu M
Biomed Pharmacother; 2020 Jul; 127():110183. PubMed ID: 32388241
[TBL] [Abstract][Full Text] [Related]
70. The role of Src in solid tumors.
Wheeler DL; Iida M; Dunn EF
Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
[TBL] [Abstract][Full Text] [Related]
71. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
Johnson TK; Soellner MB
Bioconjug Chem; 2016 Jul; 27(7):1745-9. PubMed ID: 27266260
[TBL] [Abstract][Full Text] [Related]
72. SRC kinase inhibitors: an update on patented compounds.
Schenone S; Brullo C; Musumeci F; Radi M; Castagnolo D
Curr Med Chem; 2011; 18(33):5061-78. PubMed ID: 22050754
[TBL] [Abstract][Full Text] [Related]
73. The Relevance of the SH2 Domain for c-Src Functionality in Triple-Negative Breast Cancer Cells.
Mayoral-Varo V; Sánchez-Bailón MP; Calcabrini A; García-Hernández M; Frezza V; Martín ME; González VM; Martín-Pérez J
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530373
[TBL] [Abstract][Full Text] [Related]
74. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
75. Signalling through SH2 and SH3 domains.
Mayer BJ; Baltimore D
Trends Cell Biol; 1993 Jan; 3(1):8-13. PubMed ID: 14731533
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of N1-Src kinase by a specific SH3 peptide ligand reveals a role for N1-Src in neurite elongation by L1-CAM.
Keenan S; Wetherill SJ; Ugbode CI; Chawla S; Brackenbury WJ; Evans GJ
Sci Rep; 2017 Feb; 7():43106. PubMed ID: 28220894
[TBL] [Abstract][Full Text] [Related]
77. Phosphorylation of unique domains of Src family kinases.
Amata I; Maffei M; Pons M
Front Genet; 2014; 5():181. PubMed ID: 25071818
[TBL] [Abstract][Full Text] [Related]
78. Role of co- and post-translational modifications of SFKs in their kinase activation.
Cai ML; Wang MY; Zhang CH; Wang JX; Liu H; He HW; Zhao WL; Xia GM; Shao RG
J Drug Target; 2020 Jan; 28(1):23-32. PubMed ID: 31094236
[TBL] [Abstract][Full Text] [Related]
79. Regulatory Roles of the N-Terminal Intrinsically Disordered Region of Modular Src.
Kato G
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216357
[TBL] [Abstract][Full Text] [Related]
80. Computational approaches for the identification and optimization of Src family kinases inhibitors.
Poli G; Martinelli A; Tuccinardi T
Curr Med Chem; 2014; 21(28):3281-93. PubMed ID: 25005179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
